NCT06419946 2026-04-13
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Recruiting
Clinical Trials
39 trialsNCT05095376 2026-04-03
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT06388733 2026-04-01
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NeuroTrials, LLC
Phase 3 Recruiting
NCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT07452458 2026-03-05
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NRG Oncology
Phase 3 Not yet recruiting
NCT07195591 2026-03-04
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT06448286 2026-02-19
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 3 Not yet recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT02685605 2025-10-14
INTRAGO-II
Universitätsmedizin Mannheim
Phase 3 Active not recruiting
NCT03345095 2025-07-01
MIRAGE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT05439278 2025-05-21
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Severance Hospital
Phase 3 Recruiting
NCT05271240 2024-09-19
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
Phase 3 Recruiting
NCT06477939 2024-06-27
THREE-GLEES
Institut de cancérologie Strasbourg Europe
Phase 3 Not yet recruiting
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT00482677 2023-08-22
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 3 Completed
NCT05718466 2023-07-17
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
Phase 3 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT02761070 2023-03-08
RE-GEND
Kyorin University
Phase 3 Unknown
NCT05600491 2022-10-31
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
Sun Yat-sen University
Phase 3 Unknown
NCT03243461 2022-06-06
HIT-HGG-2013
University of Göttingen
Phase 3 Unknown
NCT03419403 2021-04-14
UNITE Study: Understanding New Interventions With GBM ThErapy
AbbVie
Phase 3 Terminated
NCT04829097 2021-04-02
Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3 Unknown
NCT00884741 2019-07-24
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT03633552 2018-08-16
Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
Mashhad University of Medical Sciences
Phase 3 Unknown
NCT01765088 2018-02-23
A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
Sun Yat-sen University
Phase 3 Unknown
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT01149109 2017-06-14
CeTeG
University Hospital, Bonn
Phase 3 Completed
NCT00335075 2017-05-15
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00916409 2017-04-10
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
NovoCure Ltd.
Phase 3 Completed
NCT01830101 2016-03-16
A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase 3 Withdrawn
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00689221 2014-11-04
CENTRIC
EMD Serono
Phase 3 Completed
NCT00052455 2013-12-18
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00006353 2012-09-24
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT01502241 2011-12-30
Methusalem
Heidelberg University
Phase 3 Completed
NCT00820963 2011-05-12
Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 3 Completed
NCT00615186 2011-02-10
Glass-Art
Bradmer Pharmaceuticals Inc.
Phase 3 Terminated
NCT00068952 2008-04-01
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Pfizer
Phase 3 Completed